Antwerp, Flemish Region, Belgium
๐๐ซ๐ข๐๐ ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐๐ฉ ๐๐๐ญ๐ฐ๐๐๐ง ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐๐๐ข๐๐ข๐๐ง๐๐ฒ ๐๐ง๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ฎ๐๐๐๐ฌ๐ฌ ๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐๐๐ก๐๐ฏ๐ข๐จ๐ซ๐๐ฅ ๐๐๐ข๐๐ง๐๐. For decades, the pharmaceutical industry has faced a stagnant "retention crisis." Despite massive investments in patient-centricity, early dropout rates remain locked at 25%โ30%, and nearly 70% of protocol deviations are directly linked to unmanaged patient behavior. These aren't just administrative hurdles; they are invisible threats that erode statistical power, force 20%โ30% over-enrollment, and significantly delay market entry. As an International Executive Consultant and Advisory Board Member, I help pharmaceutical leaders transform patient adherence from a baseline risk into a deciding Unique Selling Proposition (USP) for market access. ๐๐ญ๐ซ๐๐ญ๐๐ ๐ข๐ ๐๐๐ฅ๐ฎ๐ ๐๐จ๐ซ ๐-๐๐๐ฏ๐๐ฅ & ๐๐๐ซ๐ค๐๐ญ ๐๐๐๐๐ฌ๐ฌ ๐๐๐๐๐๐ซ๐ฌ: In a shift toward value-based pricing, regulators and payers no longer just look at trial efficacyโthey look at real-world persistence. My work focuses on securing reimbursement by proving that a therapy can deliver its clinical promise in the real world. By embedding disease-agnostic behavioral models during the clinical stage, we justify higher valuations and ensure long-term commercial success. ๐๐ฉ๐๐ซ๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐ฑ๐๐๐ฅ๐ฅ๐๐ง๐๐ ๐๐จ๐ซ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐ฉ๐ฌ & ๐&๐: Data integrity is only as strong as the patientโs willingness to follow the protocol. Through the Adherence Risk Management (ARM) framework and the Subjective Health Experience (SHE) model, I provide teams with predictive behavioral modeling. Instead of reacting to deviations after they happen, we identify at-risk patients early, deploying personalized support to protect data sets and keep trials on timeline. ๐๐ฒ "๐๐ก๐ฒ": From my early days in manual labor as a builder to my 30-year career in international management, my driver has always been to create value out of raw materials. Today, those "materials" are the behavioral insights that make healthcare more sustainable for everyone. ๐ณ๐๐โ๐ ๐๐๐๐๐๐๐ ๐๐ ๐ ๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐๐๐ ๐๐๐๐ ๐น&๐ซ ๐๐๐๐๐๐๐๐๐๐. Keywords: Clinical Trial Optimization, Patient Adherence, Behavioral Science, Market Access, Data Integrity, R&D Efficiency, Value-Based Pricing, SHE Model, B-COMPASS model.
Together with the other team members I will work on promoting and nurturing actual an confident collaboration with patients and patient organizations to improve study design, study execution, and patient retention in clinical research.
As Chief Growth Officer (CGO) at PACE Clinical Iโm responsible for driving the strategic expansion of the companyโs behavioral science and adherence services. Our primary mission is to partner with our clients to solve the stagnant "retention crisis" in their clinical trials, where dropout rates have remained at 25%โ30% for decades, and to protect data integrity by addressing the 70% of protocol deviations linked to unmanaged patient behavior. In this role I bridge the gap between Clinical R&D efficiency and Commercial Market Access, positioning patient adherence as a deciding Unique Selling Proposition (USP) for pharmaceutical companies seeking value-based pricing. My Key Responsibilities are: โข Strategic Business Development: Connect with pharmaceutical C-level executives (R&D and Market Access) and CRO leaders to adopt and implement PACE Clinical's behavior-based adherence solutions. โข Commercialization of Behavioral Models: Scale the implementation of predictive frameworks, such as the Subjective Health Experience (SHE) & B-COMPASS models and our Adherence Risk Management (ARM) services, to identify at-risk patients before deviations occur. โข Market Access Strategy: Advise clients on how to leverage clinical adherence data to justify higher product valuations and secure reimbursement by proving real-world persistence. โข Partnership Management: Arrange high-level collaborations with public-private scientific consortia (e.g., BEAMER Project), patient organizations, and international industry groups to maintain PACE Clinical's position at the forefront of adherence innovation. โข Thought Leadership: Represent PACE Clinical at global symposiums and in industry publications to advocate for a transition from passive administrative metrics to active, behavior-driven compliance frameworks.
Together with the other fellows of the Collaborative for Health Systems Innovation, led by Prof. Dr. Douglas Slakey, MD, MPH, Chair of the Department of Health Systems Science (HSS), I will help to advance a holistic and unified perspective on Health Systems Science. Dr. Slakey's visionary approach brings together healthcare, business, technology, and policy, breaking down silos to foster collaboration and drive meaningful, lasting change. My key focus will be to integrate findings from the BEAMER project into the Thomas F. Frist, Jr. College of Medicine curriculum, making Belmont University the first in the United States to introduce future healthcare professionals to an innovative, personalized approach to enhancing treatment adherence.
I will continue supporting companies on their strategies and business development activities, but this time as an independent consultant. My focus is primarily on companies servicing the pharmaceutical and healthcare industry, but I'm happy to extend to other industries I have been active in.
Currently, we do not fully understand all the factors that influence patientsโ decisions regarding their treatments. The BEAMER project aims to add to our understanding of the factors that influence patient adherence across disease areas, and deliver guidance that various stakeholders could use to address patientsโ needs and boost adherence. The project will create a model of the main factors affecting patient adherence to treatment and test it in pilot studies involving 18 000 patients in multiple countries. This will allow the project team to define non-adherence and develop guidance that healthcare stakeholders could transform into tools and solutions to improve adherence. The model will not be disease specific, but it will be possible for users to add disease-specific elements. This will make the model more widely applicable to different groups of patients.